Mandate

Vinge advises Mylan on its offer for Meda

February 12, 2016

Mylan N.V. has announced a recommended public offer to the shareholders of Meda AB (publ) to tender all their shares in Meda to Mylan. The total offer consideration consists of a combination of cash and Mylan ordinary shares. At announcement, the total value of the offer for all Meda shares, including Meda net debt, is approximately SEK 83.6 billion or USD 9.9 billion.
 
In connection with the offer, Mylan has retained Vinge as legal advisor in Sweden. The Vinge team is led by public M&A partners Erik Sjöman and Charlotte Levin and also includes Rikard Lindahl, Anna Edström and Malte Hedlund (on M&A matters), Mikael Ståhl, Louise Brorsson Salomon and Albert Wållgren (on finance matters), Fredrik Gustafsson (on compensation and benefits matters) and Maria Schultzberg (on tax matters).

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026